Form D · Pharmaceuticals
Seres Health, Inc.
Cambridge, MA · CIK 0001609809
Offering snapshot reported Jan 5, 2015 · SEC filing
- Reported sold
- $65M Offering amount: $65M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 19, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 5, 2015 | Initial | $64,999,998 | No comparison | 1 | SEC filing |
| Dec 2, 2014 | Initial | $47,999,977 | No comparison | 20 | SEC filing |
| Jun 9, 2014 | Initial | $10,628,990 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-231428
Source: Form D, filed Jan 5, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Noubar Afeyan | Director |
| John Aunins | Executive |
| Greg Behar | Director |
| David Berry | Director |
| Werner Cautreels | Director |
| David Cook | Executive |
| Peter Barton Hutt | Director |
| Richard Kender | Director |
| Lorence Kim | Director |
| Roger J. Pomerantz | Director, Executive |
| Eric D. Shaff | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
161 First Street Suite 2 C
Cambridge, MA, 02142
Cambridge, MA, 02142